Table 1.
Study dosage (mg/day) | N patients | HAM-D score baseline | HAM-D score at the end | P-value* | CGI-S/CGI-I score | CGI-I/CGI-S score at the end | P-value* |
---|---|---|---|---|---|---|---|
Loo et al41 | |||||||
Agomelatine 25 mg | 135 | 27.4±2.7 | 12.8±8.2 | P=0.034 | 4.7±0.7 | 2.8±1.4 | P=0.42 |
Paroxetine 20 mg | 144 | 27.3±3.4 | 13.1±8.4 | P=0.030 | 4.9±0.7 | 2.8±1.5 | P=0.51 |
Placebo | 136 | 27.4±3.1 | 15.3±18.9 | 5.0±0.7 | 3.3±1.5 | ||
Kennedy and Emsley42 | |||||||
Agomelatine 25–50 mg | 106 | 26.5±2.8 | 14.1±7.7 | P=0.026 | 4.8±0.7 | 3.2±1.3 | P=0.017 |
Placebo | 105 | 26.7±3.0 | 16.5±7.4 | 4.8±0.7 | 3.6±1.3 | ||
Olie and Kasper43 | |||||||
Agomelatine 25–50 mg | 116 | 27.4±2.7 | 13.9±7.7 | P=0.002 | 4.9±0.7 | 3.2±0.3 | P=0.017 |
Placebo | 119 | 27.2±2.7 | 17.0±7.9 | 4.9±0.7 | 3.6±1.3 | ||
Lemoine et al45 | |||||||
Agomelatine 25–50 mg | 165 | 25.9±3.2 | 9.9±6.6 | P=0.154 | 3.2±0.8 | 1.6±0.7 | P=0.016 |
Venlafaxine 75–150 mg | 167 | 26.0±3.3 | 11.0±7.4 | 3.6±0.9 | 1.6±0.8 | ||
Kennedy et al46 | |||||||
Agomelatine 50 mg | 137 | 27.9±4.1 (MADRS) | 10.1±7.8 (MADRS) | P=0.751 | 4.4 (NR) | NR | NR |
Venlafaxine ER 150 mg | 139 | 27.9±4.6 (MADRS) | 9.8±7.9 (MADRS) | 4.5 (NR) | NR | ||
Kasper and Hajak47 | |||||||
Agomelatine 25–50 mg | 150 | 26.1±2.8 | 10.3±7.0 | P=0.031 | 4.7±0.7 | 2.5±1.1 | P=0.043 |
Sertraline 50–150 mg | 157 | 26.5±3.0 | 12.1±8.3 | 4.7±0.7 | 2.8±1.3 | ||
Goodwin et al51 | |||||||
24 weeks | |||||||
Agomelatine 25–50 mg | 165 | 6.1±2.6 | 7.5±7.0 | P≤0.001 | 1.8±0.8 | 2.1±1.2 | P=0.009 |
Placebo | 174 | 6.0±2.7 | 10.6±8.4 | 1.8±0.7 | 2.6±1.5 |
Notes: Values are mean (±SD). P-value:
denotes difference in final score for agomelatine-treated patients versus final score for comparator patients.
Abbreviations: CGI-I, Clinical Global Impression Improvement Scale; CGI-S, Clinical Global Impression-Severity Scale; ER, extended release; HAM-D, Hamilton Depression Rating Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; NR, not reported; SD, standard deviation; N, number.